2019 news: FDA Approves Cladribine
2019 news: FDA Approves Cladribine
https://www.nationalmssociety.org/About ... %C2%AE-for
March 29, 2019
UPDATED 4/2/19 with additional details and FAQs
SUMMARY
The U.S. Food and Drug Administration has approved oral cladribine (brand named Mavenclad®- EMD Serono) for the treatment of adults with relapsing forms of MS, including relapsing-remitting MS and active secondary progressive MS, based on clinical trials showing it could decrease the number of relapses and slow the accumulation of physical disability caused by MS, compared to placebo. Because of its safety profile, Mavenclad is generally recommended in people with MS who have had an inadequate response to, or are unable to tolerate, another MS therapy.
Mavenclad is a compound that targets certain types of white blood cells (lymphocytes) that drive the immune attack in MS. It temporarily reduces the number of both T and B lymphocytes without continuous suppression of the immune system.
Mavenclad has a boxed warning due to an increased risk of cancers and risk of fetal (unborn baby) harm.
Potential safety issues identified by the FDA include decrease in white blood cells, and increased risk of infections and liver injury. The most common adverse reactions reported during clinical trials included upper respiratory tract infections, headache, and low white blood counts.
Mavenclad is taken by mouth in two treatment courses, twelve months apart.
“This is an important breakthrough for people who do not respond to alternatives that have been approved to treat relapsing-remitting or active secondary progressive MS,” said Kathy Costello, MS, ANP-BC, MSCN, Associate Vice President of Healthcare Access at the National MS Society. “We are grateful that there is an additional option for people affected by these forms of MS.”
take control of your own health.
pursue optimal self care, with or without a diagnosis.
Re: 2019 news: FDA Approves Cladribine
https://mssociety.ca/research-news/arti ... mitting-ms
Mavenclad (cladribine) approved for use by the NHS in England and Wales (2017)
https://www.mstrust.org.uk/news/news-ab ... -and-wales
MAVENCLAD (CLADRIBINE) IS ADDED TO THE PHARMACEUTICAL BENEFITS SCHEME (2018) (Australia)
https://msra.org.au/news/mavenclad-clad ... ts-scheme/
take control of your own health.
pursue optimal self care, with or without a diagnosis.
-
- Similar Topics
- Replies
- Views
- Last post
-
-
2019 review: Mg for CV Health (and more)
by jimmylegs » Fri May 10, 2019 3:32 pm » in Natural Approach - 0 Replies
- 1296 Views
-
Last post by jimmylegs
Fri May 10, 2019 3:32 pm
-
-
-
2019: lifestyle and depression in MS
by jimmylegs » Sat Jun 01, 2019 4:02 pm » in Mental & Spiritual Health - 0 Replies
- 1123 Views
-
Last post by jimmylegs
Sat Jun 01, 2019 4:02 pm
-
-
- 0 Replies
- 835 Views
-
Last post by frodo
Tue Sep 24, 2019 1:23 am
-
-
Biomarkers: Status at the end of 2019
by frodo » Fri Dec 27, 2019 11:53 am » in MS Etiology and Pathogenesis - 0 Replies
- 619 Views
-
Last post by frodo
Fri Dec 27, 2019 11:53 am
-
-
-
Lassman review for 2019. Top four MS papers.
by frodo » Mon Jan 20, 2020 12:51 am » in MS Etiology and Pathogenesis - 0 Replies
- 931 Views
-
Last post by frodo
Mon Jan 20, 2020 12:51 am
-
-
-
2019 review: MS exercise guidelines
by jimmylegs » Sun May 12, 2019 3:45 pm » in Exercise and Physical Therapy - 0 Replies
- 1202 Views
-
Last post by jimmylegs
Sun May 12, 2019 3:45 pm
-
-
-
2019 review: Nutrition in medical education
by jimmylegs » Wed Feb 19, 2020 5:11 am » in General Discussion - 0 Replies
- 1342 Views
-
Last post by jimmylegs
Wed Feb 19, 2020 5:11 am
-
-
- 1 Replies
- 237 Views
-
Last post by NHE
Thu Aug 20, 2020 3:32 pm
-
- 0 Replies
- 589 Views
-
Last post by NHE
Tue Jun 30, 2020 8:35 am